Abstract

Introduction: Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition associatedwith poor clinical outcomes if not treated adequately. Eculizumab has become the standard of care, whereasravulizumab, a second-generation, high-affinity complement C5 inhibitor, demonstrates comparable efficacyin improving renal function, hematological markers, and dialysis rates. In addition, ravulizumab offers practicaladvantages, including a longer dosing interval and immediate, complete, and sustained inhibition of free C5,making it a valuable therapeutic option.Methods: Given the limited real-world experience with ravulizumab, we present a case series of six treatmentnaïveaHUS patients who received ravulizumab as first-line therapy.Results: These cases include one pregnancy-related aHUS, one postpartum case, one related to a urinary tractinfection, one associated with hypertension, one with a pneumonia-related trigger, and one kidney transplantpatient with a prior verotoxin-producing E. coli infection. Altogether, these cases illustrate the challenges in diagnosing aHUS. The choice to administer ravulizumab as first-line treatment was sometimes made in the presence of a clear clinical suspicion, even when not all minor criteria seemed to confirm the diagnosis. In most patients, renal function improved rapidly after ravulizumab administration, followed by recovery of hematological parameters, which were stable in the longer term. As improvements remained sustained over time, the possibility of discontinuing ravulizumab can be evaluated on a case-by-case basis.Conclusion: These cases highlight the importance of early diagnosis, prompt intervention, and multidisciplinarycare in managing aHUS. Ravulizumab as first-line therapy proved effective and well-tolerated, with sustainedclinical improvements observed across diverse real-world scenarios.

Affiliated Institutions

Related Publications

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Publication Info

Year
2025
Type
article
Volume
19
Issue
1
Pages
99-107
Citations
0
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

0
OpenAlex

Cite This

Livia Maria Sorrentino, Candida Iacuzzo, Raffaella Sciri et al. (2025). Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series. Drug Target Insights , 19 (1) , 99-107. https://doi.org/10.33393/dti.2025.3616

Identifiers

DOI
10.33393/dti.2025.3616